Eisai Co., Japan's fourth-largest drugmaker, said it bought the rights to develop and sell Massachusetts-based Sepracor Inc.'s Lunesta sleeping pill in its home market.
The drug, which has the generic name eszopiclone, is in the first of three stages in Japan of patient studies generally required for regulatory review, Tokyo-based Eisai said Friday.